DT · Dynatrace

The thesis

Dynatrace is modestly more likely than not to beat the S&P 500 over the next three months. The company raised its fiscal 2027 revenue and annual recurring revenue (ARR) outlook on 3 November 2026 and authorized a new $1 billion buyback, while the shares fell 32.3% over nine sessions to a $43.44 close on 6 November 2026, per Trefis. The S&P 500 fell 3.9% over the same stretch. Whether organic ARR growth holds near 16% decides whether the sell-off overshot, and the first scheduled test is the investor day on 16 February 2027.

The shares closed at $44.90 on 12 November 2026, 32.3% below the 52-week intraday high of $66.30 set on 13 October 2026. That price has already removed the re-rating that built up through October ahead of the report, so the market is now pricing the lower margin outlook and the unchanged organic growth rate.

The September quarter showed steady growth, not acceleration. Total ARR was $2,207 million, up 16%. Revenue of $580 million rose 17%. Non-GAAP (adjusted) operating margin was 32%, and non-GAAP earnings per share were $0.54, per the company's 3 November 2026 release. MarketBeat put the consensus estimate at $0.49.

Bullish and bearish views on Dynatrace, Inc.

The bull case on Dynatrace, Inc. (DT), in brief: full-year outlook went up. The bear case: earnings and cash flow guidance fell.

Bull case

• Full-year outlook went up. Fiscal 2027 revenue guidance rose to $2,330–$2,340 million from $2,306–$2,320 million. The ARR range rose to $2,393–$2,413 million from $2,359–$2,379 million, per the company's 3 November 2026 release.
• A much larger buyback. The board added $1 billion on 3 November 2026, bringing remaining capacity to about $1.3 billion. Dynatrace repurchased 5.2 million shares for $246 million in the September quarter at an average of $47.38, above the $44.90 close on 12 November 2026.
• Profitability beat the quarter's own run rate. The September quarter's 32% non-GAAP operating margin compares with 29% in the June quarter. Third-quarter revenue guidance of $591–$596 million implies growth of 15% to 16%.
• Arize adds an AI product line. The acquisition closed on 1 October 2026. The company says it adds about 200 basis points to fiscal 2027 ARR growth at a cost of about 175 basis points of non-GAAP operating margin.
• Most brokers kept positive ratings. Post-report targets (3 November to 4 November 2026) were UBS $75 from $80, Citigroup $70, RBC Capital $68, Needham $65, Wells Fargo $65, Rosenblatt $65 and BTIG $63, all above the $44.90 close. Goldman Sachs maintained its Buy rating and lowered its target on 11 November 2026, per company news.

Bear case

• Earnings and cash flow guidance fell. Fiscal 2027 non-GAAP operating margin guidance dropped to 28%–28.25% from 29.5%–29.75%. Non-GAAP earnings per share guidance fell to $1.88–$1.90 from $1.97–$1.99, and adjusted free cash flow guidance to $600–$605 million from $610–$615 million.
• The ARR raise matches Arize. Constant-currency ARR growth guidance rose to 17.5%–18.5% from 15.5%–16.5%, a gain of about 200 basis points, equal to the stated Arize contribution. On this note's reading, the organic outlook is roughly unchanged.
• Share count outlook rose. Diluted weighted average shares are now guided at 306–308 million, up from 295–297 million, which lowers earnings per share for a given profit.
• Cash flow was thin in the quarter. Adjusted free cash flow was $42.3 million, a 7% margin, against $309 million and 56% in the June quarter, per the company's releases.
• Reported profit trails adjusted profit. GAAP operating margin was 16% against 32% non-GAAP in the September quarter. Trefis put the trailing price-to-earnings ratio at 77.3 on 6 November 2026, against a 27.9 median for S&P 500 technology stocks.
• Targets are being cut. Barclays lowered its target to $61, Cantor Fitzgerald to $50 and Wedbush to $50 on 4 November 2026. J.P. Morgan adjusted its target on 6 November 2026, and Goldman Sachs lowered its on 11 November 2026.

Price setup

The shares closed between $43.44 (6 November 2026) and $44.90 (12 November 2026) in the six sessions from 5 November 2026, per daily closes. The 3-month change is –8.6% from the $49.14 close on 14 August 2026.

The 200-day average of $44.75 sits just under the last close. The 50-day average of $56.53 sits well above it, a gap left by the October rally and the November fall. The 52-week closing low is $32.36 on 10 April 2026.

Market value fell about $6.0 billion during the nine-session slide, leaving about $12.5 billion on 6 November 2026, per Trefis. Seven brokers raised targets between 20 October 2026 and 27 October 2026, before the report.

SEC Form 4 filings show the chief technology officer sold 50,000 shares at $57.21 on 18 September 2026 under a Rule 10b5-1 plan. Other recent insider filings, through 19 October 2026, are option exercises with shares withheld for tax. No open-market insider purchases appear in the filings since mid-August.

Catalysts ahead

• 16 February 2027: Dynatrace investor day, outlining a path to a 'Rule of 50' in fiscal 2029. Management's first chance to reset long-term growth and margin targets after the lower fiscal 2027 margin and earnings outlook; it shows whether organic ARR growth near 16% is the company's base case.
• ~5 February 2027 (est.): Third-quarter fiscal 2027 results (date not yet confirmed by the company). First report with Arize in the numbers; shows whether ARR growth holds at or above 16% and whether the 26% non-GAAP operating margin guide is met.

What would change the view

A daily close below $38, under the $38.88 average price Dynatrace paid for shares repurchased in the June 2026 quarter, which would put the shares below what the company itself paid. A cut to fiscal 2027 constant-currency ARR growth guidance, excluding Arize, would also break the case.

The risks this note tracks, each with what would confirm it:

• Organic ARR growth slows further while Arize masks the underlying trend in the reported outlook. Confirmed by: total ARR growth below the 16% reported for the September quarter, or a cut to the constant-currency outlook after removing Arize, at the next quarterly report.
• Margin and per-share earnings keep drifting lower as Arize costs and a higher share count enter results. Confirmed by: third-quarter non-GAAP operating margin below the 26% guided, or a diluted share count above the 306–308 million outlook.
• Cash conversion weakens after a thin September quarter. Confirmed by: adjusted free cash flow tracking below the $600–$605 million full-year guidance.
• Analyst targets continue to fall, extending the sell-off. Confirmed by: further target cuts or rating downgrades beyond the November 2026 round.

What it trades with

Dynatrace trades with software that sells observability and AI monitoring tools. Trefis said the nine-session slide was mostly specific to Dynatrace, since the S&P 500 fell 3.9% over the same stretch. One software-trade report in the period attributed a separate Dynatrace decline to broader software multiple compression. Analyst target changes have moved the shares more than index moves in the two weeks since the report.